/ pharma stocks
/ Market Analysis
BioNTech Seals $1.25B CureVac Deal to Accelerate Cancer Treatment Development
BioNTech's $1.25 billion acquisition of CureVac creates a "German biotech champion" focused on mRNA-based cancer treatments, with CureVac shares surging 38% on ...
June 12, 2025
Why Did Lyra Therapeutics’ Stock Rocket Past 440% in Premarket Today
Lyra Therapeutics stock surged in premarket trading after announcing positive Phase 3 trial results for a key treatment.
June 02, 2025
Novo Nordisk’s Shares Dip Amid Surprise CEO Exit in Challenging Times for the Firm
Novo Nordisk's surprise CEO departure amid mounting competitive pressures and disappointing clinical results has accelerated the stock's 50% decline since mid-2024.
May 16, 2025
NVO vs LLY: Which Pharma Stock is Likely to Do Better in 2025?
Obesity market continues to boom, with Novo Nordisk opening the gates wide open with Wegovy.
May 13, 2025
Eli Lilly’s Stock Tumbles as Firm Cuts EPS Guidance Despite Strong Q1
Eli Lilly's stock dropped over 7% after announcing a lowered profit forecast, despite exceeding Q1 expectations.
May 01, 2025More from The Tokenist / pharma stocks
Trump Admin. Reconsiders $590M Funding for Moderna’s Bird Flu Vaccine
February 27, 2025
Moderna Slashes R&D Budget, Stock Plummets Amid Profitability Concerns
September 12, 2024
Back to 
